

**Arab Center For Pharmaceutical & Chemical Industries Company**

**(Public Shareholding Company)**

**Amman Jordan**

**Interim condensed Financial Statements for**

**The period ended March 31, 2026**

**With Auditors' report**

Arab Center For Pharmaceutical & Chemical Industries Company

(Public Shareholding Company)

Amman Jordan

March 31, 2026

Table of contents

Auditors' report

Notes

Consolidated Interim Statement of Financial Position

A

Consolidated Interim Statement of Profit or Loss

B

Consolidated Interim Statements of changes in equity

C

Consolidated Interim Statement of Cash Flows

D

Notes to Consolidated Financial Statements

1 -4



**KHALIFEH & RAYYAN**

Auditors and Financial Consultants

## **Review Report**

**To the esteemed Chairman and Members of the Board of Directors**  
**Arab Center For Pharmaceutical & Chemical Industries Company**  
**Public Shareholding Company**  
**Amman, Jordan**

### **Introduction**

We have reviewed the attached condensed interim consolidated financial statements of **Arab Center For Pharmaceutical & Chemical Industries Company (a Public Shareholding Company)**, which comprise the interim consolidated statement of financial position as of March 31, 2026, the interim consolidated statement of comprehensive income, the interim consolidated statement of changes in equity, and the interim consolidated statement of cash flows for the three-months period ended on that date. The preparation and presentation of the condensed consolidated financial data in accordance with International Accounting Standard (IAS) 34, "Interim Financial Reporting," are the responsibility of the company's management. Our responsibility is to issue a report on these statements based on our review procedures.

### **Scope of Review**

We conducted our review in accordance with the International Standard on Review Engagements (ISRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." This review primarily consisted of performing analytical procedures on the financial information and making inquiries of the officials responsible for financial and accounting matters of the company. Our review procedures are substantially less in scope than an audit conducted in accordance with International Standards on Auditing (ISAs). Because a review does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit, we do not express an audit opinion on the attached condensed interim consolidated financial statements.

### **Significant Doubt About Company's Continuity**

We would like to draw attention to Note No. (4) in the interim financial statements, where the accumulated losses of the company as of the statement of financial position date amounted to JOD 8,868,768, representing 177% of the company's share capital. In addition, total current liabilities exceeded current assets by JOD 2,732,239.

These matters may affect the company's ability to continue in the future, and its continuation depends on securing the necessary financing to settle its obligations and on the success of its future operations. The company has submitted a comprehensive plan to ensure its going concern.

## Conclusion

Based on our review procedures performed, we have not become aware of any material modifications that should be made to the attached condensed interim consolidated financial statements in order for them to be in accordance with International Accounting Standard (IAS) 34, "Interim Financial Reporting."

## Emphasis of Matter Paragraph

We draw attention to the following matters:

- There are attachments and legal liens on the company's land, buildings, vehicles, machinery, and bank current accounts, in addition to a restriction on the company's registration as reflected in the company's registration certificate with the Ministry of Industry and Trade – Companies Control Department.
- We also draw attention to Note No. (5), which indicates that the construction-in-progress project, which commenced in March 2013 and is still ongoing to date, has not been completed. It is noted that the dispute with the contractor is currently under arbitration for settlement.

**Khalifeh & Rayyan Auditors and Financial Consultants**

**Imad Al-Rayyan**

**License No. 719**

  
**KHALIFEH & RAYYAN**  
Auditors And Financial Consultants

**Amman – Jordan**

**As on: 22 of April 2026**



**Arab Center For Pharmaceutical & Chemical Industries**  
**Public Shareholding Company**  
**Interim Statement of Financial Position AS AT 31 Mar 2026**

	<u>Notes</u>	<u>31-Mar-26</u>	<u>31-Dec-25</u>
		JOD	JOD
<b>Assets</b>			
<b>Non-Current assets</b>			
Properties and equipments		4,425,055	4,430,803
Investment in an associate company	3	0	0
Due from related parties		5,542	5,542
Financial assets at fair value (Comprehensive income)		1	1
		<u>4,430,597</u>	<u>4,436,345</u>
<b>Current assets</b>			
Inventory		91,963	81,620
Other Debit balances		51,642	51,808
Trade receivables		86	1
<b>Total Current assets</b>		<u>143,691</u>	<u>133,429</u>
<b>TOTAL ASSETS</b>		<u>4,574,289</u>	<u>4,569,775</u>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Declared and paid in capital		5,000,000	5,000,000
Statutory reserve		1,138,105	1,138,105
Accumulated changes in fair value of financial assets		(115,457)	(115,457)
Accumulated losses		(8,868,786)	(8,865,940)
<b>Net Equity</b>		<u>(2,846,137)</u>	<u>(2,843,292)</u>
<b>LIABILITIES</b>			
<b>Non -Current liabilities</b>			
Due from shareholders		4,544,496	4,544,496
<b>Total non -current liabilities</b>		<u>4,544,496</u>	<u>4,544,496</u>
<b>Current liabilities</b>			
Due to related parties		1,561,981	1,564,716
Shareholders' deposits		208,330	208,330
Other credit balances		687,784	685,271
Trade payable		417,835	410,255
<b>Total current liabilities</b>		<u>2,875,930</u>	<u>2,868,572</u>
<b>Total liabilities</b>		<u>7,420,426</u>	<u>7,413,067</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u>4,574,289</u>	<u>4,569,775</u>

(The accompanying notes are an integral part of these financial statements)

**Arab Center For Pharmaceutical & Chemical Industries**  
**Public Shareholding Company**  
**Interim Statement of Profit or Loss For the three months ended**

	<u>31-Mar-26</u>	<u>31-Mar-25</u>
	JOD	JOD
Sales	37,444	33,219
Cost of sales	<u>(28,873)</u>	<u>(26,306)</u>
<b>Gross profit (loss)</b>	<b>8,571</b>	<b>6,913</b>
Other income	9,079	6,825
Administrative expenses	<u>(20,496)</u>	<u>(15,036)</u>
<b>Profit (loss) for the period</b>	<b><u>(2,846)</u></b>	<b><u>(1,298)</u></b>
<b>Other comprehensive income items:</b>		
Changes in fair value of financial assets	<u>-</u>	<u>-</u>
<b>Total comprehensive income (loss) for the period</b>	<b><u>(2,846)</u></b>	<b><u>(1,298)</u></b>
Weighted average numbers of shares	5,000,000	5,000,000
Basic and diluted earnings (loss) per share	(0.0006)	(0.0003)

(The accompanying notes are an integral part of these financial statements)

**Arab Center For Pharmaceutical & Chemical Industries**  
**Public Shareholding Company**  
**Interim Statement of Cash Flows For the three months ended**

	<u>31-Mar-26</u>	<u>31-Mar-25</u>
	JOD	JOD
<b>Operating activities</b>		
Profit (loss) for the period	(2,846)	(1,298)
<b>Adjustments for:</b>		
Depreciation	5,747	5,746
<b>Net Operating Cash Profit (Loss)</b>	<u>2,902</u>	<u>4,448</u>
<b>Changes in working capital</b>		
Inventory	(10,343)	(6,196)
Other Debit balances	166	4,335
Trade receivables	(85)	667
Other credit balances	2,513	(3,766)
Trade payable	7,580	(4,767)
<b>Total Changes in Working Capital Items</b>	<u>(168)</u>	<u>(9,727)</u>
<b>Net cash from operating activities</b>	<u>2,734</u>	<u>(5,279)</u>
<b>Investing activities</b>		
Proceeds from disposal of property and equipment	-	-
<b>Net cash from operating activities</b>	-	-
<b>Financing activities</b>		
Due to related parties	(2,734)	5,741
<b>Net cash from financing activities</b>	<u>(2,734)</u>	<u>5,741</u>
<b>Net changes in cash and cash equivalent</b>	-	462
Cash and cash equivalent at beginning of period	-	-
<b>Cash and cash equivalent at end of period</b>	<u>-</u>	<u>462</u>

(The accompanying notes are an integral part of these financial statements)

**Arab Center For Pharmaceutical & Chemical Industries**  
**Public Shareholding Company**

**Interim Statements of changes in equity for the three months ended at 31 Mar 2026**

	<u>Paid in capital</u>	<u>Statutory reserve</u>	<u>Accumulated changes in fair value</u>	<u>Accumulated losses</u>	<u>Total equity</u>
	JOD	JOD	JOD	JOD	JOD
<b>Balance as at 01/01/2026</b>	5,000,000	1,138,105	(115,457)	(8,865,940)	(2,843,292)
Total comprehensive loss for the period				(2,846)	(2,846)
<b>Balance as at 31/03/2026</b>	<u>5,000,000</u>	<u>1,138,105</u>	<u>(115,457)</u>	<u>(8,868,786)</u>	<u>(2,846,138)</u>
<b>Balance as at 01/01/2025</b>	5,000,000	1,138,105	(115,457)	(8,829,316)	(2,806,668)
Total comprehensive income for the period				(1,298)	(1,298)
<b>Balance as at 31/03/2025</b>	<u>5,000,000</u>	<u>1,138,105</u>	<u>(115,457)</u>	<u>(8,830,614)</u>	<u>(2,807,966)</u>

(The accompanying notes are an integral part of these financial statements)



**Arab Center For Pharmaceutical & Chemical Industries**  
**NOTES TO THE INTERIM FINANCIAL STATEMENTS**  
**31 March 2026**

**1- GENERAL**

Arab Center For Pharmaceutical & Chemical Industries Company, was established as a Public Shareholding Company on 05 July 1983 under number (260). The company's head office is in the Hashemite Kingdom of Jordan.

The main objectives and purposes of the company are as follows:

- \* Manufacturing of human pharmaceutical liquid dosage forms
- \* Manufacturing of human pharmaceutical tablets
- \* Manufacturing of human pharmaceutical suppositories
- \* Manufacturing of veterinary antibiotics
- \* Manufacturing of veterinary antibacterial products
- \* Manufacturing of veterinary vitamins and anti-infective products
- \* Manufacturing of gelatin capsules

The accompanying interim financial statements were approved by the Company's Board of Directors on 22 April 2026.

**2- Summary of significant accounting policies**

**A- Basis of preparation**

The financial statements of the Company have been prepared in accordance with International Financial Reporting Standards.

The financial statements have been prepared on a historical cost basis, except for financial assets which have been measured at fair value.

The financial statements are presented in Jordanian Dinar which is the functional currency of the Company.

The accounting policies are consistent with those used in the previous year, except for the adoption of new and amended standards effective as at the beginning of the period.

**B- Accounting estimates and judgements**

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

**3- Investment in an associate company**

	<u>31-Mar-26</u>	<u>31-Dec-25</u>
	JD	JD
Cost (Middle East Pharmaceutical & Chemical Industries Co.)	394,016	394,016
Share of the company in the results of the associated company	(394,016)	(394,016)
	<u>-</u>	<u>-</u>

**4- Accumulated losses**

The accumulated losses of the company as of the statement of financial position date amounted to JOD 8,868,786, representing 177% of the company's share capital. In addition, the company's current liabilities exceeded its current assets by JOD 2,732,239, which may affect the company's ability to continue as a going concern and requires compliance with Article No. (266) of the Jordanian Companies Law.